Chimeric antigen receptor (CAR) T cells have emerged as a potent therapeutic approach for
patients with certain haematological cancers, with multiple CAR T cell products currently …

Chimeric antigen receptor (CAR)‐T cell therapies have improved the outcome for many
patients with relapsed or refractory aggressive B‐cell lymphomas. In 2017, axicabtagene …

Chimeric antigen receptor (CAR) T-cell therapy has emerged as an option for
relapsed/refractory aggressive B-cell lymphomas that have failed 2 lines of therapy. Failures …

Abstract Disease Overview Diffuse large B‐cell lymphoma (DLBCL) is the most common
type of aggressive non‐Hodgkin lymphoma originating from the germinal center, and it …

Adoptive cell therapies (ACTs) have existed for decades. From the initial infusion of tumor-
infiltrating lymphocytes to the subsequent specific enhanced T cell receptor (TCR)-T and …

Adoptive cellular immunotherapy with chimeric antigen receptor (CAR) T cell has changed
the treatment landscape of B-cell non-Hodgkin's lymphoma (NHL), especially for aggressive …

Two autologous anti‐CD19 chimeric antigen receptors (CAR) T cells (axicabtagene
ciloleucel [axi‐cel] and tisagenlecleucel [tisa‐cel]) are commercially approved in Europe for …

PURPOSE Two anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapies are approved
for diffuse large B-cell lymphoma, axicabtagene ciloleucel (axi-cel) and tisagenlecleucel; …

The development of chimeric antigen receptor (CAR) T‐cell therapy for select hematological
malignancies represents one of the most remarkable therapeutic advances in the past …

Cytokine release syndrome (CRS) immune effector cell–associated neurotoxicity syndrome
are the most notable toxicities of CD19 chimeric antigen receptor (CAR) T-cell therapy. In …